Patent · US Active

Predicting likelihood of response to combination therapy

US10253369B2 · kind B2 · utility

0Cited by

2References

18Claims

0Family size

Assignee

BIOTHERANOSTICS, INC. · US

Inventors

Catherine A. Schnabel · San Diego, US
Yi Zhang · Nanjing, CN
Mark G. Erlander · Encinitas, US

Key dates

Filing date	May 28, 2015
Grant date	Apr 9, 2019
Priority date	—
Expiry date	Jan 21, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Provided are methods of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy. Also provided are methods of treating a subject having ER+ breast cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.